IBDEI1FS ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1051,0)
 ;;=PREGNANCY-LATE PREGNANCY^8^108
 ;;^UTILITY(U,$J,358.4,1052,0)
 ;;=PREGNANCY-PUERPERAL INFECTIONS^14^108
 ;;^UTILITY(U,$J,358.4,1053,0)
 ;;=PREGNANCY-MULTIPLE GESTATIONS^9^108
 ;;^UTILITY(U,$J,358.4,1054,0)
 ;;=PREGNANCY-OTH COMP OF PUERPERIUM^11^108
 ;;^UTILITY(U,$J,358.4,1055,0)
 ;;=PREGNANCY-OTHER COMPLICATIONS^10^108
 ;;^UTILITY(U,$J,358.4,1056,0)
 ;;=PREGNANCY-OTHER CONDITIONS^12^108
 ;;^UTILITY(U,$J,358.4,1057,0)
 ;;=PREGNANCY-PROBLEMS W/ AMNIO/MEMBRANES^13^108
 ;;^UTILITY(U,$J,358.4,1058,0)
 ;;=PREGNANCY-PYREXIA^15^108
 ;;^UTILITY(U,$J,358.4,1059,0)
 ;;=PREGNANCY-V CODES^16^108
 ;;^UTILITY(U,$J,358.4,1060,0)
 ;;=PREGNANCY-VENOUS COMPLICATIONS^17^108
 ;;^UTILITY(U,$J,358.4,1061,0)
 ;;=PREGNANCY-VOMITING^18^108
 ;;^UTILITY(U,$J,358.4,1062,0)
 ;;=V CODES^19^108
 ;;^UTILITY(U,$J,358.4,1063,0)
 ;;=SPECIAL SERVICES^9^109
 ;;^UTILITY(U,$J,358.4,1064,0)
 ;;=CHEMO NURSE PROCEDURES^2^109
 ;;^UTILITY(U,$J,358.4,1065,0)
 ;;=INFUSION DRUGS^6^109
 ;;^UTILITY(U,$J,358.4,1066,0)
 ;;=BLOOD PRODUCTS^1^109
 ;;^UTILITY(U,$J,358.4,1067,0)
 ;;=DIAGNOSTIC PROCEDURES^3^109
 ;;^UTILITY(U,$J,358.4,1068,0)
 ;;=OTHER DRUGS^7^109
 ;;^UTILITY(U,$J,358.4,1069,0)
 ;;=IMMUNIZATION ADMINISTRATION^4^109
 ;;^UTILITY(U,$J,358.4,1070,0)
 ;;=IMMUNIZATIONS^5^109
 ;;^UTILITY(U,$J,358.4,1071,0)
 ;;=PROLONGED SERVICES^8^109
 ;;^UTILITY(U,$J,358.4,1072,0)
 ;;=NEW PATIENT^2^110
 ;;^UTILITY(U,$J,358.4,1073,0)
 ;;=ESTABLISHED PATIENT^1^110
 ;;^UTILITY(U,$J,358.4,1074,0)
 ;;=CONSULTATIONS^3^110
 ;;^UTILITY(U,$J,358.4,1075,0)
 ;;=ANEMIA^1^111
 ;;^UTILITY(U,$J,358.4,1076,0)
 ;;=COAGULATION DISORDERS^4^111
 ;;^UTILITY(U,$J,358.4,1077,0)
 ;;=MYELOID NEOPLASMS & DISORDERS^12^111
 ;;^UTILITY(U,$J,358.4,1078,0)
 ;;=LYMPHOID NEOPLASMS^9^111
 ;;^UTILITY(U,$J,358.4,1079,0)
 ;;=GI NEOPLASMS^7^111
 ;;^UTILITY(U,$J,358.4,1080,0)
 ;;=HEAD, NECK & LUNG NEOPLASMS^8^111
 ;;^UTILITY(U,$J,358.4,1081,0)
 ;;=MISC. NEOPLASMS^11^111
 ;;^UTILITY(U,$J,358.4,1082,0)
 ;;=METASTATIC SITES^10^111
 ;;^UTILITY(U,$J,358.4,1083,0)
 ;;=COUNSELING & SCREENING^5^111
 ;;^UTILITY(U,$J,358.4,1084,0)
 ;;=GENITOURINARY NEOPLASMS^6^111
 ;;^UTILITY(U,$J,358.4,1085,0)
 ;;=BREAST & GYN NEOPLASMS^3^111
 ;;^UTILITY(U,$J,358.4,1086,0)
 ;;=ARTIFICIAL OPENING STATUS^2^111
 ;;^UTILITY(U,$J,358.4,1087,0)
 ;;=PERSONAL HX OF CANCER^15^111
 ;;^UTILITY(U,$J,358.4,1088,0)
 ;;=NEOPLASMS OF UNCERTAIN BEHAVIOR^13^111
 ;;^UTILITY(U,$J,358.4,1089,0)
 ;;=NEOPLASMS OF UNSPECIFIED NATURE^14^111
 ;;^UTILITY(U,$J,358.4,1090,0)
 ;;=ESTABLISHED PATIENT^1^112
 ;;^UTILITY(U,$J,358.4,1091,0)
 ;;=CONSULTATION-CLINICIAN^2^112
 ;;^UTILITY(U,$J,358.4,1092,0)
 ;;=NEW PATIENT^3^112
 ;;^UTILITY(U,$J,358.4,1093,0)
 ;;=NEUROLYSIS^1^113
 ;;^UTILITY(U,$J,358.4,1094,0)
 ;;=NEUROSTIMULATORS^2^113
 ;;^UTILITY(U,$J,358.4,1095,0)
 ;;=OTHER PROCEDURES^3^113
 ;;^UTILITY(U,$J,358.4,1096,0)
 ;;=SPINAL PROCEDURES/NERVE BLOCKS^4^113
 ;;^UTILITY(U,$J,358.4,1097,0)
 ;;=SYMPTOMS^5^114
 ;;^UTILITY(U,$J,358.4,1098,0)
 ;;=ESTHESOPATHIES & ALLIED SYNDROMES^1^114
 ;;^UTILITY(U,$J,358.4,1099,0)
 ;;=HEADACHE^2^114
 ;;^UTILITY(U,$J,358.4,1100,0)
 ;;=SPINAL CONDITIONS^4^114
 ;;^UTILITY(U,$J,358.4,1101,0)
 ;;=PAIN^3^114
 ;;^UTILITY(U,$J,358.4,1102,0)
 ;;=PEER SERVICES^1^115
 ;;^UTILITY(U,$J,358.4,1103,0)
 ;;=ADJUSTMENT DISORDERS^2^116
 ;;^UTILITY(U,$J,358.4,1104,0)
 ;;=ANXIETY DISORDERS^3^116
 ;;^UTILITY(U,$J,358.4,1105,0)
 ;;=ORGANIC DISORDERS^10^116
 ;;^UTILITY(U,$J,358.4,1106,0)
 ;;=DEMENTIA^6^116
 ;;^UTILITY(U,$J,358.4,1107,0)
 ;;=BIPOLAR DISORDERS^4^116
 ;;^UTILITY(U,$J,358.4,1108,0)
 ;;=PSYCHOSIS/OTHER^13^116
